Evidence map›Paper›PMID 34162400›Full record

ArticleJournal of neuroinflammation2021

Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.

Dong-Ling Liu, Zhi Hong, Jing-Ying Li, Yu-Xin Yang, Chu Chen, Jun-Rong Du

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Efferocytosis in the Central Nervous System.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Dong-Ling LiuDepartment of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, PR China.
Zhi HongDepartment of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, PR China.
Jing-Ying LiDepartment of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, PR China.
Yu-Xin YangDepartment of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, PR China.
Chu ChenSichuan Academy of Chinese Medicine Sciences, Chengdu, 610041, PR China.
Jun-Rong DuDepartment of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, PR China. dujr_1@163.com.
Sichuan University · CNCenter for High Pressure Science & Technology Advanced Research · CNSichuan Academy of Traditional Chinese Medicine · CN

Funding

Department of Science and Technology of Sichuan Province 2014JY0151Department of Science and Technology of Sichuan Province 2018SZ0015National Natural Science Foundation of China 81072636National Natural Science Foundation of China 81473219
6 · The paper itself

Abstract

backgroundHemorrhagic transformation (HT) is a critical issue in thrombolytic therapy in acute ischemic stroke. Damage-associated molecular pattern (DAMP)-stimulated sterile neuroinflammation plays a crucial role in the development of thrombolysis-associated HT. Our previous study showed that the phthalide derivative CD21 attenuated neuroinflammation and brain injury in rodent models of ischemic stroke. The present study explored the effects and underlying mechanism of action of CD21 on tissue plasminogen activator (tPA)-induced HT in a mouse model of transient middle cerebral artery occlusion (tMCAO) and cultured primary microglial cells.

methodsThe tMCAO model was induced by 2 h occlusion of the left middle cerebral artery with polylysine-coated sutures in wildtype (WT) mice and macrophage scavenger receptor 1 knockout (MSR1

resultsSeventy-two hours after brain ischemia, CD21 significantly attenuated neurobehavioral dysfunction and infarct volume. The tPA-infused group exhibited more severe brain dysfunction and hemorrhage. Compared with tPA alone, combined treatment with tPA and CD21 significantly attenuated ischemic brain injury and hemorrhage. Combined treatment significantly decreased Evans blue extravasation, matrix metalloproteinase 9 expression and activity, extracellular Prx1 content, proinflammatory cytokine mRNA levels, glial cells, and Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB) pathway activation and increased the expression of tight junction proteins (zonula occludens-1 and claudin-5), V-maf musculoaponeurotic fibrosarcoma oncogene homolog B, and MSR1. MSR1 knockout significantly abolished the protective effect of CD21 against tPA-induced HT in tMCAO mice. Moreover, the CD21-induced phagocytosis of Prx1 was MSR1-dependent in cultured primary microglial cells from WT and MSR1

conclusionThe phthalide derivative CD21 attenuated tPA-induced HT in acute ischemic stroke by promoting MSR1-induced DAMP (Prx1) clearance and inhibition of the TLR4/NF-κB pathway and neuroinflammation.

Indexed as

Cerebral HemorrhageAnimalsBenzofuransBrainCell LineDisease Models, AnimalInfarction, Middle Cerebral ArteryIschemic StrokeMaleMiceMice, Inbred C57BLNF-kappa BPeroxiredoxinsReceptors, ScavengerReperfusionTissue Plasminogen ActivatorBenzofuransNF-kappa BPeroxiredoxinsphthalide derivative CD21Receptors, ScavengerTissue Plasminogen ActivatorToll-Like Receptor 4DAMP (peroxiredoxin 1) clearanceHemorrhagic transformationIschemic strokeMSR1NeuroinflammationTissue plasminogen activatorTLR4/NF-κB pathway

Identifiers

PMID34162400
PMCPMC8223381
OpenAlexW3176502225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.